Preventing Lung Cancer in Patients with Bronchial Dysplasia
Name of the Trial
Why Is This Trial Important?
Zileuton (Zyflo) is a drug used to prevent asthma symptoms, and it is being studied in the prevention of cancer. It belongs to the family of drugs called lipoxygenase inhibitors. Lipoxygenases produce chemical substances called leukotrienes that promote inflammation. Inflammation may be involved in the development of some cancers, including lung cancer. This trial will study the effectiveness of zileuton in eliminating bronchial dysplasia in smokers and former smokers who are at high risk for lung cancer.
"So far there is no effective chemopreventive agent for lung cancer," said Dr. Kucuk. "But we know that in animal studies, lipoxygenase inhibitors like zileuton prevent lung cancer from developing.
"With this study, we hope to see zileuton prevent precancerous lesions from progressing in humans, thus paving the way for larger, more conclusive cancer prevention studies with this class of drugs," Dr. Kucuk added. "It's a proof-of-principle study.
"Who Can Join This Trial?
Where Is This Trial Taking Place?
Who to Contact
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.